KNSA
KNSA
GB00BRXB0C07
Kiniksa Pharmaceuticals Interna
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 90/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±53.7% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.0x).

Beta (Market Relation)
0.04x
Defensive
Volatility (5Y p.a.)
53.7% p.a.
5-Year Horizon
Max Drawdown (5Y)
-49.8%
5-Year Horizon
Sharpe Ratio
0.84
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — +105.6%
3 Years 47.1% -34.1% 1.4 +68.2%
5 Years 53.7% -49.8% 0.84 +47.7%
10 Years 63.4% -83.1% 0.25 —

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 79.8 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (53.7% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -83.1% in the extended horizon.

Corporate Governance & ISS Scores

Shareholder rights, board structure and audit safety (Scale 1 = Low Risk, 10 = High Risk)
Overall Governance Risk
9 ISS Score: 9 / 10
Audit Risk
7 ISS Score: 7 / 10
Board Risk
8 ISS Score: 8 / 10
Short Ratio
7.89
ende